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A B S T R A C T   
We developed a simplified, highly efficient Gateway reaction that recombines target DNA to expression (desti-
nation) plasmids in vivo and subsequently conjugates the final vector into a recipient strain, all in a single step. 
This recipient strain does not need to contain any selective marker and can be freely chosen as long as it is 
sensitive to ccdB counterselection and can be targeted by the RP4α conjugation system. Our protocol is simple, 
robust, and cost effective. It works in 96-well plate format and performs across a range of temperatures. We 
designed modular, minimal destination vectors containing a modified Gateway insert to ease vector design by 
providing locations for insertion of tags, promoters, or conjugations. To demonstrate the utility of our system, we 
created destination vectors with split adenylate cyclase tags for bacterial two-hybrid (B2H) studies and screened 
a library of diguanylate cyclases for protein-protein interactions in a single step.   
1. Introduction 
Gateway cloning technology was developed by Invitrogen in the 
1990s to enable fast and reliable (sub-) cloning by site directed recom-
bination (Hartley et al., 2000). Gateway technology relies on the specific 
recombination of att sites on the DNA catalyzed by BP or LR Clonase 
enzymes, which enable translocation of genetic elements between DNA 
strands based on conserved sequences (Liang et al., 2013). Most appli-
cations of this technology rely on the use of purified enzymes. House 
et al., described a set of engineered bacterial strains that eliminate the 
need for purified enzymes and are able to recombine DNA between 
plasmids by an elegant combination of bacterial conjugation, in vivo 
recombination and selectable as well as counterselectable markers 
(House et al., 2004). In this work, we have created a simplified and 
versatile in vivo Gateway system that can produce the recombined 
destination vector in a recipient strain in a single step following library 
construction. We have reduced the number of bacterial strains necessary 
to perform the recombination and, importantly, use auxotrophic 
markers that enable us (largely) free choice of the final strain from 
which the recombined vector can be recovered. 
To expand on current in vivo Gateway technologies, we developed a 
3-strain in vivo Gateway system consisting of a donor strain, worker 
strain, and helper strain to perform the Gateway reaction and subse-
quent transfer of the recombined plasmid into a recipient strain in a 
single-step reaction (Fig. 1). The reaction consists of the donor strain 
transferring the donor vector into the worker strain, which contains the 
destination vector and the excision and integrase enzymes expressed by 
an inducible promoter. The LR clonase reaction occurs within the 
worker strain and the final plasmid containing the gene within the 
destination vector is transferred into the recipient strain. The recipient 
strain with the final vector is selected for by loss of ccdB, the plasmid 
selectable marker, and the recipient strain selectable marker or positive 
selection against the reaction strains. To aid in selection, we developed 
the system within the diaminopimelic acid dependent Escherichia coli 
MFDpir strain, allowing positive selection and thus removing the 
requirement of a unique selection marker in the recipient strain. This 
includes an E. coli MFDpir CcdB-resistant strain. We tested the system 
utilizing the CcdB resistant E. coli strain DB3.1 as the worker strain, 
which significantly increased reaction efficiency, but requires a unique 
selectable marker in the recipient strain. 
In designing the system, we constructed modular minimal destina-
tion vectors that allow easy insertion of Gateway constructs. The mini-
mal destination vectors were created with an RP4 origin of transfer and 
compatible origins of replication (p15a or pBM1) with antibiotic 
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resistance markers encoding ampicillin (bla), gentamycin (aacC1), or 
tetracycline (tetA, tetR) resistance to create pANG01, pANG02, and 
pANG03, respectively. Each minimal destination vector includes a 
modified Gateway cassette consisting of the site-specific recombination 
sites (attR1, attR2), a chloramphenicol resistance gene (cat) and a 
counterselectable marker (ccdB). The cassette is flanked by unique re-
striction sites (PmeI-attR1-cat-ccdB-attR2-PacI) to allow for easy inser-
tion of C- and N-terminal tags. Our destination vectors were paired with 
the donor vector pMARO, a pMK2010 derived plasmid, containing the 
same RP4 origin of transfer (oriT), kanamycin resistance (aph(3′)) and 
the pBR332 origin of replication (House et al., 2004). To facilitate the 
Gateway reaction, we utilized the vector pXint129 encoding the excision 
(xis) and integrase (int) genes, kanamycin resistance, and no origin of 
transfer (Platt et al., 2000). The plasmid pRK2013 contains the conju-
gation machinery to facilitate the transfer of plasmids containing the 
RP4 oriT (Flgurski and Helinski, 1979). 
The system developed offers several improvements to the Gateway 
system. Our scaled down reaction is performable in micro centrifuge 
tubes or in a 96-well plate over a range of temperatures and conditions 
without requiring a unique selectable marker in the recipient strain. The 
modular nature of our designed vectors allows for the easy incorporation 
of tags, promoters, or conjugations to the gene of interest. The reaction 
also allows for selection of the final vector construct in the recipient 
strain of choice, assuming it is CcdB sensitive, in a single step. We 
demonstrate the utility of this system by designing a bacterial 2-hybrid 
system and screen several genes using sequential in vivo Gateway re-
actions to incorporate multiple vectors into a reporter strain to screen for 
protein-protein interactions. 
2. Material and methods 
2.1. Vector construction 
The minimal destination vectors were constructed by PCR amplifi-
cation then Gibson assembly of PCR fragments (Gibson et al., 2009). 
pANG01 (GenBank OK571346) was constructed with the bla from 
pGP704, oriTRP4 from pG704, and the oriVp15a from pBAD33 (Guzman 
et al., 1995; Miller and Mekalanos, 1988). pANG02 (GenBank 
OK571347) was constructed with the aacC from a pGP704-gentR 
construct, oriTRP4 from pG704, and oriVpBM1 from pET28b (Sigma, Cat. 
69865). The vectors were constructed to introduce unique EcorV, SpeI, 
and XhoI sites between fragments (Table S2, Supp. Methods). pANG03 
(GenBank OK571348) was constructed by replacing the bla resistance 
gene from pANG01 with tetA-tetR from pRK415 (Keen et al., 1988). The 
Gateway sequence was synthesized based off the commercial vector 
pDONR201 (Invitrogen) and inserted into the EcorV sites of minimal 
vectors by Gibson assembly to include unique PmeI and PacI restriction 
sites flanking the att sites (Section 3, Supp. Methods). Bacterial 2-hybrid 
T25 and T18 along with the lactose promoter (plac) and terminator se-
quences were incorporated in the PmeI and PacI sites following restric-
tion enzyme digestion then Gibson assembly using the commercial 
vectors pKT25, pKNT25, pUT18, and pUT18C (Euromedex, EUP-25N/ 
25C/18N/18C) to construct the plasmids pAH01-08 (Table S3, Supp. 
Methods). The donor vector pMARO (GenBank OK571349) was con-
structed from pMK2010 by insertion of the tetA-tetR cassette flanked by 
EcorV sites between the attP sites by the BP clonase reaction. This allows 
for creation of entry vectors either by restriction digest with EcorV to 
linearize the vector then using blunt end ligation or Gibson Assembly to 
insert the gene of interest, or by BP clonase reaction of pMK2010. The 
tetA-tetR cassette is also cut by EcorV, which reduces background and 
allowing ligation by Gibson Assembly without subsequent purification 
steps. Sequences are listed in supplementary methods. 
2.2. Strains 
The E. coli strain MFDpir was obtained from Andrea Moell (Boston, 
MA) and E. coli DB3.1 obtained commercially (Invitrogen, 11782-018) 
(Ferrieres et al., 2010). In this study, a λ-pir variation of DB3.1 E. coli 
was used to complement E. coli MFDpir so that all strains could support 
plasmid containing R6K origins of replication if required. Use of λ-pir 
variants of E. coli DB3.1 or MFD should not be required for plasmids not 
dependent on λ-pir. MFDpir was made CcdB resistant by transformation 
with the ccdB containing pANG01 and confirmed by curing and re- 
transformation with other destination vectors. Rifampicin resistant 
recipient strains E. coli DH5α (NEB, C2987) and E. coli BTH101 (Euro-
medex, EUB001) were made by serial plating on LB agar containing 
rifampicin (50 μg/ml) until resistant colonies arose. 
2.3. In vivo gateway reaction 
All strains are grown separately with corresponding antibiotics 
resistance encoded on the plasmid(s) in LB media (Sigma, L3022 or 
L2897) with the donor strain carrying pMARO using kanamycin (50 μg/ 
ml), the worker strain carrying the destination vector using carbenicillin 
(50 μg/ml), gentamycin (20 μg/ml), or tetracycline (12 μg/ml) in 
combination with kanamycin (50 μg/ml), and the helper strain carrying 
pRK2013 using kanamycin (50 μg/ml). When grown, E. coli MFDpir is 
supplemented with diaminopimelic acid (57 μg/ml). The three in vivo 
Gateway strains: donor, worker, and helper along with the recipient 
strain are grown overnight in LB broth containing the corresponding 
antibiotics. Cultures are pelleted and decanted, washed twice and sus-
pended in equal volumes of phosphate buffered saline (PBS). Equal 
volumes of each culture (125 μl for micro centrifuge tubes, 50 μl for 96- 
well plates) are combined and concentrated 10-fold by pelleting and 
resuspension in PBS. The concentrated suspension is placed as a single 
droplet onto a 0.45 μm MCE membrane (Millipore, HAWP04700) on top 
of LB agar containing diaminopimelic acid (57 μg/ml) and 1 mM iso-
propyl β-d-1-thiogalactopyranoside (IPTG) and incubated at 37 ◦C for 
20–24 h with the filter side facing up. Following incubation, the filter is 
placed in a 12 ml conical test tube containing 1 ml PBS and vortexed for 
30 s to suspend the pellet. The suspension is serial diluted in PBS and 
Fig. 1. Schematic of in vivo Gateway reaction. The donor vector pMARO con-
taining the gene or DNA of interest is transferred via conjugation to the working 
strain containing the customizable destination vector pDest (pANG01-03 or 
pAH01-08) that contains a unique antibiotic marker (abx). The helper strain 
with the pRK2013 plasmid aids in conjugation between strains. Gateway 
excision (xis) and integrase (int) enzymes expressed by pXint129 in the working 
strain and facilitate transfer of the gene from the donor vector into the desti-
nation vector. At the same time, the cat-ccdB cassette is transferred to the donor 
vector. The final construct enters the recipient strain by conjugation. After se-
lection on media without diaminopimelic acid and with antibiotics, the auxo-
troph E. coli MFDpir strains die and only the recipient strain containing the 
destination plasmid and its antibiotic resistance gene but lacking the ccdB gene 
can survive. If using E. coli DB3.1 as a worker strain a unique counterselectable 
marker is required within the recipient strain. 
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plated for single colonies on LB agar containing the destination vector 
antibiotic without diaminopimelic acid and antibiotics selecting only for 
the recipient strain are incorporated (e.g. rifampicin) if using E. coli 
DB3.1 as the worker strain. Single colonies typically appear with a 1:100 
dilution with DB3.1, and with a 1:10 dilution using an MFDpir worker 
strain. 
2.4. Bacterial 2-hybrid 
For bacterial 2-hybrid assays, the adenylate cyclase deficient re-
porter E. coli strain BTH101 (F-, cya-99, araD139, galE15, galK16, rpsL1 
(Str r), hsdR2, mcrA1, mcrB1, Rif r) was used as the recipient strain for 
the in vivo Gateway reaction. A paired set of bacterial 2-hybrid vectors 
pAH01-04 derived from pANG01 backbone or pAH05-08 derived from 
pANG02 backbone were used for screening. In vivo Gateway reactions 
were performed in two steps, incorporating each pair of plasmids and 
genes sequentially. For heterodimer screening E. coli BTH101 pAH04- 
VC2697 was first constructed and used as a recipient strain for all tested 
genes cloned into pAH06. After construction, interactions were screened 
by growing the BTH101 pAH04-VC2697 and pAH06-Gene combinations 
in LB containing carbenicillin (50 μg/ml), gentamicin (20 μg/ml), and 1 
mM IPTG overnight at 37 ◦C with shaking. Overnight cultures were then 
spot plated (3 μl) on MacConkey agar (Sigma, M7408) supplemented 
with 2% maltose, carbenicillin (50 μg/ml), gentamicin (20 μg/ml), and 
1 mM IPTG and grown at 30 ◦C for 24–48 h. 
3. Results and discussion 
To test the maximum reaction efficiency of the in vivo Gateway 
system, we incorporated the tetracycline resistance cassette (tetA-tetR) 
into pMK2010, creating pMARO. By selecting for the recipient strain 
utilizing the destination vector resistance (carbenicillin) and tetracy-
cline, we select for both the loss of ccdB and the complete insert trans-
ferring correctly. This is expected to reduce the background of incorrect 
inserts or loss of CcdB activity and allow us to better estimate the 
maximum efficiency of the reaction. 
The in vivo Gateway reaction was tested using scalable benchtop 
conditions. The donor and helper strains are replaceable with E. coli 
MFDpir and still maintain high reaction efficiency while utilizing E. coli 
DB3.1 as a worker strain (Fig. 2A). Replacing the worker strain with the 
CcdB resistant E. coli MFDpir still functions, albeit significantly reducing 
reaction efficiency (45 Colony Forming Units (CFU)/Reaction, 22–68 
95% CI). E. coli MFDpir is diaminopimelic acid dependent by deletion of 
dapA. Using only the auxotrophic E. coli MFDpir strains removes the 
need for negative selection against the donor, worker, and helper strains 
in the recipient strain. Decreasing the temperature reduces the reaction 
efficiency (Fig. 2B), but still produces reasonable colony counts across 
20–37 ◦C, allowing for temperature sensitive plasmids or strains as 
destination vectors or recipient strains. We tested the effect of bacterial 
density during the Gateway reaction. We concentrated increasing vol-
umes of the same overnight cultures, re-suspended cells in the same 
small volume and placed on the filter covered agar plate. Unexpectedly, 
we observed decreased reaction efficiency with increased cell volume, i. 
e. increased numbers of cell and increased bacterial densities on the 
filter (Fig. 2C). Additionally, when the reaction was performed in 96- 
well plates with 50 μl volumes, we did not observe a significant differ-
ence between 125 μl culture volumes in micro centrifuge tubes (Fig. 2D). 
Overall, the reaction performed equally well in micro centrifuge tubes or 
96 well plates, allowing for scalable benchtop reactions. 
Transfer of the tetracycline resistance cassette into a CcdB sensitive 
strain determined the maximum reaction yield, with selection for both 
the gene to transfer intact and in the correct backbone. However, when 
the insert is not selectable, colonies could result from other ways that 
disrupt ccdB function (e.g. spontaneous non-sense mutations). To 
address this possibility, three non-selectable cyclic-di-guanosine mono-
phosphate (c-di-GMP) producing genes from Vibrio cholerae were chosen 
to test the reaction in the destination vector pANG03. The plate counts 
for the recipient strain following the in vivo Gateway reaction with the 
DB3.1 worker strain were similar for the selectable and non-selectable 
inserts (Fig. 3A, Range 6.4 × 103–1.6 × 104). From each reaction, 16 
colonies were picked and patched onto LB agar containing rifampicin 
(50 μg/ml) and tetracycline (12 μg/ml) for growth to confirm presence 
of the destination vector. Lack of growth on LB agar containing chlor-
amphenicol (20 μg/ml) confirmed loss of Gateway cassette (Fig. 3B). 
Colony PCR (Supp. Methods) was used to determine the insert size, and 
in all cases (48/48) was determined to be the correct size (Fig. 3B, C). 
Overall the reaction efficacy was determined to be 92.6–100% (95% CI, 
Wilson's Method), which means only a handful of colonies need to be 
screened to find a positive clone. 
To test the applicability of the in vivo Gateway system, we developed 
bacterial 2-hybrid destination vectors. The bacterial 2-hybrid system 
relies on the dimerization of proteins tagged with the T18 and T25 
fragments of the Bordetella pertussis adenylate cyclase to restore cAMP 
production in cya deficient strains (Karimova et al., 1998). Reconstitu-
tion of cAMP production activates catabolic operons restoring maltose 
and lactose fermentation, which is measurable by acidification of Mac-
Conkey media or by blue-white screening in X-gal containing media 
(Karimova et al., 1998). The minimal vectors pANG01–02 (Fig. 4A) were 
used to generate N-terminal and C-terminal constructs containing the 
T18 and T25 fragments (Fig. 4B). The general design of the bacterial 2- 
hybrid Gateway insert is the T18 or T25 fragment inserted in frame with 
the att sites and gene with the start and stop codon removed and 
expression under control of plac. Short sequences (3–6 amino acids) 
were added to the opposite terminal of the T18 or T25 tag to incorporate 
start or stop codons in frame with the att sites. The bacterial 2-hybrid 
Gateway fragments were inserted at the EcorV site of pANG01-02 
creating paired C- and N-terminal constructs of the T18 and T25 frag-
ments (Fig. 4C). Following construction of the destination vectors, 
Fig. 2. In vivo Gateway reaction efficiency. In vivo Gateway reaction measuring 
the efficiency of transfer of the tetracycline-resistance cassette from pMARO to 
the carbenicillin-resistant destination plasmid pANG01 and transfer to the final 
recipient strain E. coli DH5α. (A) Total CFU of recipient cells containing the 
recombined final plasmids per reaction with DB3.1 or E. coli MFDpir as the 
worker strain. The reactions were performed in microcentrifuge tubes with 
0.125 ml culture volume. The effect of (B) temperature and (C) amount of over- 
night culture on reaction efficiency. (D) Efficiency of reaction in 96-well plate 
with 50 μl culture volumes. Recipient cells with recombined plasmids were 
quantified after selection on tetracycline and carbenicillin containing media. 
Volumes represent amount of each culture component before concentration. All 
data shows mean ± std. with n ≥ 3. 
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leucine zipper positive controls were cloned into the destination vectors 
in sequential 2-step in vivo Gateway reaction into the recipient strain 
E. coli BTH101. Leucine zippers self-dimerize with a non-covalent bond 
to bring together T18 and T25 fragments to restore cAMP production 
(Karimova et al., 1998). The 2-step in vivo Gateway constructs the first 
recombined destination vector into an empty recipient strain, and then 
uses the created strain with plasmid as the recipient strain for creation of 
a complimentary plasmid (Supp. Methods). All paired T18 and T25 
tagged leucine zipper positive controls were constructed with corre-
sponding negative controls: pAH01/07, pAH02/08, pAH03/05, and 
pAH04/06. All leucine zipper pairs showed positive colorimetric results 
and developed red colonies on MacCokeny reporter agar and no color 
development when tested against empty backbones (Fig. 4D). 
After development of the bacterial 2-hybrid destination vectors, we 
screened a library of diguanylate cyclases, a class of proteins known to 
dimerize, for self- and hetero-interactions (Abel et al., 2011). Typically, 
diguanylate cyclases have N-terminal interaction domains and GGDEF 
output domains that harbor the enzymatic activity. We chose the 
destination vector pair pAH04/06 to fuse the T18/25 fragment to the C- 
terminus of the diguanylate cyclases, i.e. the enzymatic domains least 
likely to impair the dimerization (Chan et al., 2004). We first screened 
genes in pAH04/06 for self-interaction using 2-step in vivo Gateway and 
identified VC2697 dimerization on MacConkey indicator media 
(Fig. 5A). Once VC2697 was identified to self-dimerize, it was tested for 
interaction with a selection of similarly structured GGDEF containing 
diguanylate cyclases (Fig. 5B). Using a single step in vivo Gateway re-
action, 10 genes were simultaneously transformed into pAH06 with 
E. coli BTH101 containing pAH04-VC2697 as the recipient strain. Col-
onies from the reaction were screened on MacConkey indicator media 
and VC1376 was found to specifically interact with VC2697 (Fig. 5B–D). 
Fig. 3. Reaction efficiency across genes. (A) Total final recombinants per re-
action with working strain E. coli DB3.1 for test genes from Vibrio cholerae 
showing mean ± std. with n = 3. (B) Results of pick and patch for growth on 
recipient strain selection (rifampicin) and plasmid backbone selection (tetra-
cycline), and loss of Gateway cassette selection (chloramphenicol). PCR positive 
denotes pick and patch colonies positive for correct sized insert. Efficiency is 
95% confidence interval (Wilson's method). (C) Representative image of results 
for gene VC2697 showing inverted color image with overlay of 1% TAE gel for 
colony PCR results for the insert of gene VC2697 (Lanes 2–17, 1108 bp ex-
pected) and non-transformed destination plasmid (Lane 18, 1756 bp expected). 
Lane 1 contains 1 kb plus ladder (NEB) with lane 19 containing DH5α colony 
PCR negative control and lane 20 with no template. 
Fig. 4. Incorporation of bacterial 2-hybrid into the in vivo Gateway system. (A) 
Shows the general plasmid backbone used for construction of the destination 
vectors and unique restriction sites. (B) The general map of the Gateway system 
incorporated into the EcorV site. (C) Plasmid list of bacterial 2-hybrid Gateway 
vectors tested in pairs with the same terminal location of corresponding T25 
and T18 tags. (D) Representative image of E. coli strain BTH101 grown on in-
dicator media with insertion of leucine zipper by in vivo Gateway into N-ter-
minal bacterial 2-hybrid vectors. Development of a red color indicates 
acidification of the media via maltose formation from restoration of adenylate 
cyclase activity. (For interpretation of the references to color in this figure 
legend, the reader is referred to the web version of this article.) 
Fig. 5. Applying in vivo Gateway bacterial 2-hybrid system experimentally. (A) 
Screening for self-interaction utilizing 2-step in vivo Gateway reaction to create 
pAH04/pAH06 combinations of paired genes. Image shows positive results for 
self-interaction of VC2697. Grid denotes combinations of plasmids. (B) 
Screening of pAH04-VC2697 against indicated gene in pAH06. A positive 
interaction with VC1376 is observed. (C) Positive and negative controls for 
pAH04 and pAH06 containing leucine zipper with grid denoting combinations 
of plasmids. (D) Conformation of VC2697 and VC1376 specific interaction with 
grid denoting combinations of plasmids. All data shows growth of plasmids in 
E. coli BTH101 on MacConkey indicator media. Development of a red color 
indicates acidification of the media via maltose formation from restoration of 
adenylate cyclase activity. (For interpretation of the references to color in this 
figure legend, the reader is referred to the web version of this article.) 
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4. Conclusions 
In this study, we developed a simplified in vivo Gateway system with 
advantages over commercially available BP/LR Clonase reaction kits. 
Our method removes the requirement of the LR clonase and provides 
cheaper alternatives for the BP clonase reaction, e.g. blunt end ligation 
or Gibson assembly. In large-scale assays, purified enzymes can be 
responsible for a large portion of costs and our system only requires 
bacterial growth media and antibiotics to perform the Gateway reaction 
following library construction. Our system also provides a modular 
framework for construction of destination vectors. Each vector is con-
structed so that the origin of replication or resistance marker can easily 
be swapped out. Additionally, our modified Gateway cassette provides 
unique restriction sites directly flanking the attR1 and attR2 sequences, 
allowing for easy insertion of tags, promoters, or conjugations to the 
gene of interest. Like other tools, this system is not a replacement but 
rather an alternative approach with benefits. Where our system could 
provide the most benefit is in large-scale screenings such as bacterial 2- 
hybrid or when cloning genes into a library of destination vectors. 
In summary, we developed a simplified in vivo Gateway system with 
modular customizable destination vectors. The system was developed 
for a range of laboratory conditions, and optimized for individual or 
scalable 96-well plate reactions. We have demonstrate the application of 
our system by incorporating the bacterial 2-hybrid into Gateway and 
screening a library of genes against a test gene in a single-step reaction. 
Combined, our system offers a new tool for the Gateway system to 
stream line cloning and transformation, and save on reagent costs. 
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